Breakdown | |||||
TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
---|---|---|---|---|---|
Income Statement | Total Revenue | ||||
789.40B | 801.81B | 751.78B | 690.46B | 648.73B | 634.31B | Gross Profit |
200.25B | 204.09B | 189.32B | 171.95B | 156.51B | 158.55B | EBIT |
42.60B | 44.50B | 41.00B | 37.45B | 34.05B | 37.34B | EBITDA |
54.42B | 61.02B | 56.53B | 49.52B | 44.26B | 46.01B | Net Income Common Stockholders |
30.18B | 30.75B | 29.13B | 25.70B | 23.85B | 25.33B |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
67.25B | 64.96B | 69.70B | 80.87B | 89.33B | 86.50B | Total Assets |
376.60B | 444.01B | 420.21B | 360.67B | 325.77B | 308.53B | Total Debt |
2.53B | 38.67B | 35.00B | 939.00M | 529.00M | 114.00M | Net Debt |
-64.72B | -26.29B | -34.70B | -79.93B | -88.80B | -86.38B | Total Liabilities |
129.88B | 174.29B | 167.12B | 124.34B | 105.18B | 103.37B | Stockholders Equity |
246.72B | 269.71B | 253.09B | 236.33B | 220.59B | 205.16B |
Cash Flow | Free Cash Flow | ||||
571.00M | 7.71B | 2.96B | 11.27B | 11.89B | 15.29B | Operating Cash Flow |
8.89B | 41.16B | 41.19B | 37.38B | 31.68B | 31.76B | Investing Cash Flow |
-26.57B | -35.37B | -74.85B | -28.51B | -20.66B | -17.90B | Financing Cash Flow |
14.12B | -10.60B | 22.49B | -17.33B | -8.19B | -8.06B |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
78 Outperform | ¥368.26B | 19.29 | 0.40% | 13.86% | 98.99% | ||
74 Outperform | $594.26B | 22.21 | 10.45% | 1.03% | 17.94% | 18.31% | |
74 Outperform | ¥534.57B | 35.49 | 1.40% | 5.56% | -43.50% | ||
71 Outperform | $554.48B | 25.41 | 4.93% | 3.26% | 4.63% | -47.30% | |
70 Outperform | ¥513.18B | 16.69 | 11.61% | 2.82% | 6.66% | 5.56% | |
70 Neutral | ¥701.67B | 23.73 | 0.74% | 6.96% | -3.96% | ||
54 Neutral | $5.37B | 3.35 | -45.10% | 2.79% | 16.77% | -0.01% |
Sundrug Co., Ltd. reported its consolidated financial results for the fiscal year ending March 31, 2025, showing a notable increase in net sales and profits compared to the previous year. The company experienced a 6.7% rise in net sales, reaching 801,811 million yen, and a 5.6% increase in profit attributable to owners of the parent, totaling 30,750 million yen. The financial results indicate a strong performance, with improvements in operating and ordinary profits, reflecting the company’s robust market positioning and operational efficiency. The company also announced an increase in annual dividends, demonstrating its commitment to returning value to shareholders.
The most recent analyst rating on (JP:9989) stock is a Buy with a Yen4100.00 price target. To see the full list of analyst forecasts on Sundrug Co stock, see the JP:9989 Stock Forecast page.